vs
EXACT SCIENCES CORP（EXAS）与STEVEN MADDEN, LTD.（SHOO）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是STEVEN MADDEN, LTD.的1.2倍（$878.4M vs $749.8M），STEVEN MADDEN, LTD.净利率更高（3.3% vs -9.8%，领先13.1%），STEVEN MADDEN, LTD.同比增速更快（29.5% vs 23.1%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $80.8M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 16.7%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Steven Madden, Ltd.是一家上市时尚企业，专注于鞋履及潮流配饰的设计与营销，总部位于纽约长岛市。旗下拥有Dolce Vita、Betsey Johnson、Blondo、BB Dakota、Mad Love等品牌，同时获得Anne Klein、Superga等品牌的授权开展相关业务。
EXAS vs SHOO — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $749.8M |
| 净利润 | $-86.0M | $24.7M |
| 毛利率 | 70.1% | 42.6% |
| 营业利润率 | -9.4% | 4.8% |
| 净利率 | -9.8% | 3.3% |
| 营收同比 | 23.1% | 29.5% |
| 净利润同比 | 90.1% | -34.8% |
| 每股收益（稀释后） | $-0.45 | $0.33 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $878.4M | $749.8M | ||
| Q3 25 | $850.7M | $664.2M | ||
| Q2 25 | $811.1M | $556.1M | ||
| Q1 25 | $706.8M | $551.4M | ||
| Q4 24 | $713.4M | $578.8M | ||
| Q3 24 | $708.7M | $621.2M | ||
| Q2 24 | $699.3M | $521.7M | ||
| Q1 24 | $637.5M | $550.6M |
| Q4 25 | $-86.0M | $24.7M | ||
| Q3 25 | $-19.6M | $20.5M | ||
| Q2 25 | $-1.2M | $-38.7M | ||
| Q1 25 | $-101.2M | $41.3M | ||
| Q4 24 | $-864.6M | $37.8M | ||
| Q3 24 | $-38.2M | $55.3M | ||
| Q2 24 | $-15.8M | $36.9M | ||
| Q1 24 | $-110.2M | $44.6M |
| Q4 25 | 70.1% | 42.6% | ||
| Q3 25 | 68.6% | 41.8% | ||
| Q2 25 | 69.3% | 40.6% | ||
| Q1 25 | 70.8% | 41.0% | ||
| Q4 24 | 69.0% | 40.7% | ||
| Q3 24 | 69.4% | 41.8% | ||
| Q2 24 | 69.8% | 41.6% | ||
| Q1 24 | 70.0% | 40.8% |
| Q4 25 | -9.4% | 4.8% | ||
| Q3 25 | -3.0% | 4.7% | ||
| Q2 25 | -0.3% | -7.2% | ||
| Q1 25 | -13.6% | 9.7% | ||
| Q4 24 | -122.8% | 8.1% | ||
| Q3 24 | -5.6% | 12.0% | ||
| Q2 24 | -3.8% | 9.0% | ||
| Q1 24 | -16.7% | 10.3% |
| Q4 25 | -9.8% | 3.3% | ||
| Q3 25 | -2.3% | 3.1% | ||
| Q2 25 | -0.1% | -7.0% | ||
| Q1 25 | -14.3% | 7.5% | ||
| Q4 24 | -121.2% | 6.5% | ||
| Q3 24 | -5.4% | 8.9% | ||
| Q2 24 | -2.3% | 7.1% | ||
| Q1 24 | -17.3% | 8.1% |
| Q4 25 | $-0.45 | $0.33 | ||
| Q3 25 | $-0.10 | $0.29 | ||
| Q2 25 | $-0.01 | $-0.56 | ||
| Q1 25 | $-0.54 | $0.57 | ||
| Q4 24 | $-4.69 | $0.49 | ||
| Q3 24 | $-0.21 | $0.77 | ||
| Q2 24 | $-0.09 | $0.49 | ||
| Q1 24 | $-0.60 | $0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $112.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $866.4M |
| 总资产 | $5.9B | $1.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $964.7M | $112.4M | ||
| Q3 25 | $1.0B | $140.0K | ||
| Q2 25 | $858.4M | $111.9M | ||
| Q1 25 | $786.2M | $147.2M | ||
| Q4 24 | $1.0B | $203.4M | ||
| Q3 24 | $1.0B | $11.1M | ||
| Q2 24 | $946.8M | $192.2M | ||
| Q1 24 | $652.1M | $143.1M |
| Q4 25 | $2.4B | $866.4M | ||
| Q3 25 | $2.5B | $850.8M | ||
| Q2 25 | $2.5B | $833.2M | ||
| Q1 25 | $2.4B | $875.3M | ||
| Q4 24 | $2.4B | $847.7M | ||
| Q3 24 | $3.2B | $833.9M | ||
| Q2 24 | $3.2B | $808.3M | ||
| Q1 24 | $3.1B | $825.2M |
| Q4 25 | $5.9B | $1.9B | ||
| Q3 25 | $5.9B | $2.0B | ||
| Q2 25 | $5.8B | $1.9B | ||
| Q1 25 | $5.7B | $1.4B | ||
| Q4 24 | $5.9B | $1.4B | ||
| Q3 24 | $6.7B | $1.5B | ||
| Q2 24 | $6.7B | $1.4B | ||
| Q1 24 | $6.4B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $91.1M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $80.8M |
| 自由现金流率自由现金流/营收 | 13.7% | 10.8% |
| 资本支出强度资本支出/营收 | 3.6% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.70× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $119.5M |
8季度趋势，按日历期对齐
| Q4 25 | $151.7M | $91.1M | ||
| Q3 25 | $219.9M | $23.4M | ||
| Q2 25 | $89.0M | $66.5M | ||
| Q1 25 | $30.8M | $-18.8M | ||
| Q4 24 | $47.1M | $103.9M | ||
| Q3 24 | $138.7M | $444.0K | ||
| Q2 24 | $107.1M | $109.5M | ||
| Q1 24 | $-82.3M | $-15.7M |
| Q4 25 | $120.4M | $80.8M | ||
| Q3 25 | $190.0M | $8.6M | ||
| Q2 25 | $46.7M | $58.8M | ||
| Q1 25 | $-365.0K | $-28.7M | ||
| Q4 24 | $10.7M | $94.6M | ||
| Q3 24 | $112.6M | $-6.9M | ||
| Q2 24 | $71.2M | $104.2M | ||
| Q1 24 | $-120.0M | $-19.7M |
| Q4 25 | 13.7% | 10.8% | ||
| Q3 25 | 22.3% | 1.3% | ||
| Q2 25 | 5.8% | 10.6% | ||
| Q1 25 | -0.1% | -5.2% | ||
| Q4 24 | 1.5% | 16.3% | ||
| Q3 24 | 15.9% | -1.1% | ||
| Q2 24 | 10.2% | 20.0% | ||
| Q1 24 | -18.8% | -3.6% |
| Q4 25 | 3.6% | 1.4% | ||
| Q3 25 | 3.5% | 2.2% | ||
| Q2 25 | 5.2% | 1.4% | ||
| Q1 25 | 4.4% | 1.8% | ||
| Q4 24 | 5.1% | 1.6% | ||
| Q3 24 | 3.7% | 1.2% | ||
| Q2 24 | 5.1% | 1.0% | ||
| Q1 24 | 5.9% | 0.7% |
| Q4 25 | — | 3.70× | ||
| Q3 25 | — | 1.14× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.46× | ||
| Q4 24 | — | 2.75× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | 2.96× | ||
| Q1 24 | — | -0.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
SHOO
暂无分部数据
